Add BrightSurf on Google Email

Rheumatoid arthritis drug effective against myasthenia

A randomized clinical trial found that rituximab significantly improved disease control in patients with new-onset myasthenia gravis, reducing the need for cortisone treatments and hospitalizations. The study's results offer hope for a more effective treatment strategy, but larger studies are needed to assess long-term effects.

SourceKarolinska Institutet·JournalJAMA Neurology·TypeRandomized controlled/clinical trial·DateSep 19, 2022

Online yoga programs may improve knee function in the short term

A randomized trial found that a 12-week online yoga program improved knee function in participants, but did not significantly reduce knee pain during walking. The study suggests that unsupervised online yoga programs can be feasible and improve physical function, but more research is needed to sustain the effectiveness.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateSep 19, 2022

C-Path awarded FDA grant to establish public-private partnership to advance treatments for rare neurodegenerative diseases

The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.

Scientists have created a mathematical model for the dynamics of nanoparticles and viruses in cells

A team of scientists from Ural Federal University has developed a complex mathematical model to understand the dynamics of nanoparticles and viruses in cells. The model reveals how viruses cluster inside endosomes and interact with cellular proteins, shedding light on their behavior and replication mechanisms. This breakthrough can hel...

SourceUral Federal University·JournalCrystals·DateSep 13, 2022

Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate

A study by Case Western Reserve University has identified a promising path to developing therapies for esophageal tumors. The research team linked the TGFβ-pathway, a cell signaling mechanism, to tumor development and found that a protein-coding gene called HNF4α is a predictive biomarker of cancer.

SourceCase Western Reserve University·JournalGastroenterology·DateSep 7, 2022

Early plasma antigen levels predict illness severity and clinical outcomes in hospitalized patients with COVID-19

A large cross-sectional study found that baseline plasma antigen levels are highly associated with both the severity of pulmonary illness and clinically important patient outcomes in hospitalized COVID-19 patients. Higher antigen levels were linked to increased risk of pulmonary worsening and delayed hospital discharge.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeObservational study·DateAug 29, 2022

Time’s arrow

Researchers found that brief rapamycin exposure in early adulthood can prevent age-related decline and extend lifespan. The study used fruit flies and mice to test the effects of short-term drug administration, showing protection against intestinal pathology and increased health span.

SourceMax Planck Institute for Biology of Ageing·JournalNature Aging·TypeExperimental study·DateAug 29, 2022

ACC issues guidance to address new nonstatin therapies

The American College of Cardiology has published an expert consensus decision pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk reduction. The guidance provides recommendations for individuals at high-risk and those with familial hypercholesterolemia, ...

SourceAmerican College of Cardiology·JournalJournal of the American College of Cardiology·TypeLiterature review·DateAug 25, 2022

Psychiatrists disagree with US policy on psychoactive drugs

A national survey of US psychiatrists found discrepancies between their perceptions of certain psychoactive drugs' safety and therapeutic value and how they are categorized under the Controlled Substances Act. Psychiatrists rated psilocybin as having low misuse potential and high therapeutic potential, but it is a Schedule I drug with ...

SourceOhio State University·JournalInternational Journal of Drug Policy·TypeSurvey·DateAug 22, 2022

New insights into the mechanisms behind Crohn’s disease point to potential therapeutic target

A new study by Massachusetts General Hospital researchers suggests that certain anti-cancer drugs may target a key player in Crohn's disease, a type of inflammatory bowel disease. The study found that mutations in a specific chromatin reader, SP140, are associated with an increased risk of immune diseases like Crohn's.

SourceMassachusetts General Hospital·JournalCell·TypeExperimental study·DateAug 22, 2022

Scientists create a DNA test that identifies Lyme disease in horses

A Rutgers scientist has developed a highly sensitive DNA test that can detect Lyme disease in horses, a condition that can cause long-term complications. The test, called genomic hybrid capture assay, was tested on a sick horse and successfully identified the pathogen, allowing for early diagnosis and treatment.

SourceRutgers University·JournalJournal of Veterinary Diagnostic Investigation·TypeExperimental study·DateAug 17, 2022

Prompt recognition and treatment found effective for lung disease in patients who received new drug for advanced cancer

A comprehensive analysis of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd found that close monitoring and proactive management can reduce the risk of ILD. The study results suggest that patient awareness and ongoing education can aid in early detection.

PET scan visualization can measure effects of STING-activating drugs

Researchers have discovered a functional link between STING signaling and immunometabolism, suggesting that PET imaging could measure the pharmacodynamic effects of STING-activating drugs. This approach may enable a whole-body analysis of immune activation in humans, guiding clinical development of anti-tumor therapy.

SourceUniversity of California - Los Angeles Health Sciences·JournalJournal of Nuclear Medicine·TypeExperimental study·DateAug 10, 2022

Potential long-term treatment for asthma found

Researchers at Aston University have developed a new approach to tackle one of the underlying causes of asthma, not just its symptoms. The treatment, which targets the structural changes made by asthmatic airways, shows promising results in mice, reducing symptoms within two weeks and returning airways to near normal.

SourceAston University·JournalRespiratory Medicine·TypeExperimental study·DateAug 9, 2022

Study identifies potential targets for treating venous ulcers

A study published in eLife identified three microRNAs that may impair healing in venous ulcers, a common type of chronic wound. The findings suggest that drugs targeting these microRNAs could help facilitate healing in patients, offering new approaches for treating this painful and slow-to-heal condition.

SourceeLife·JournaleLife·DateAug 9, 2022

Researchers developed a small molecule that makes immunotherapy available to all cancer patients

Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.

SourceTel-Aviv University·JournalJournal for ImmunoTherapy of Cancer·DateAug 8, 2022

New link found that connects cell signaling pathway to development of esophageal cancers, Barrett’s syndrome

A team of researchers at Case Western Reserve University has discovered a cell signaling pathway responsible for the development of esophageal adenocarcinomas. The Ephrin B2 (EphB2) Tyrosine kinase pathway is activated during cancer growth and regulates the behavior of normal esophageal cells, making it an attractive therapeutic target.

SourceCase Western Reserve University·JournalGastroenterology·DateJul 28, 2022

High blood viscosity can predict higher risk of death in hospitalized COVID-19 patients

Hospitalized COVID-19 patients with high blood viscosity have a 60% higher death rate than those with low blood viscosity. The study suggests that checking for blood viscosity early on could help determine the best treatment course and improve outcomes.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJournal of the American College of Cardiology·TypeObservational study·DateJul 18, 2022

A new treatment approach for cystic fibrosis

A new treatment approach using antisense oligonucleotides (ASOs) may help reduce cystic fibrosis symptoms and improve quality of life for patients with a specific gene mutation. The ASO strategy tricks cells into making an imperfect but functional version of the CFTR protein, which is better than having none at all.

SourceCold Spring Harbor Laboratory·JournalNature Communications·DateJul 14, 2022

Genetic discovery to improve lung cancer treatment

Researchers at Edith Cowan University have found a genetic link between human leukocyte antigens and immunotherapy side effects in non-small cell lung cancer patients. The discovery enables doctors to tailor treatment to individual patients, reducing the risk of toxicities and improving overall outcomes.

SourceEdith Cowan University·JournalEuropean Journal of Cancer·TypeRandomized controlled/clinical trial·DateJul 13, 2022

Fewer relapses in MS with off-label drug

A phase 3 clinical trial found that patients with relapsing-remitting multiple sclerosis treated with rituximab had a five-fold lower risk of relapse compared to those receiving standard dimethyl fumarate treatment. Rituximab also showed fewer new MS plaques on magnetic resonance imaging.

SourceKarolinska Institutet·JournalThe Lancet Neurology·TypeRandomized controlled/clinical trial·DateJul 13, 2022

Should clinicians reconsider standard therapy for gout?

A recent clinical trial found that low-dose benzbromarone was more effective in reducing blood urate levels in patients with renal urate underexcretion. The study showed that more participants in the benzbromarone group achieved the target blood urate level of < 6 mg/dL compared to those receiving febuxostat.

SourceWiley·JournalArthritis & Rheumatology·DateJul 7, 2022